The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer

被引：0
|
作者：
Oikawa, Masahiro
Ishida, Mayumi
Nakamura, Yoshiaki
Nishimura, Sumiko
Koga, Chinami
Saruwatari, Akihiro
Igawa, Akiko
Akiyoshi, Sayuri
Koi, Yumiko
Ohno, Shinji
机构：
[1] Kyushu Natl Canc Ctr, Dept Breast Oncol, Fukuoka, Japan
[2] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
563
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
    Fjermeros, Kamilla
    Ghannoum, Salim
    Geisler, Stephanie B.
    Bhargava, Sameer
    Tahiri, Andliena
    Klajic, Jovana
    Luders, Torben
    Fongard, Marie
    Nawaz, Meh Sameen
    Bosnjak-Olsen, Tatjana
    Buvarp, Unn-Cathrin Edvardsen
    Johanna Rosenskiold, Aino Katri
    Nguyen, Nam Thi
    Sletbak, Tone Tysko
    Seyedzadeh, Manouchehr
    Selsas, Knut
    Porojnicu, Alina Carmen
    Skjerven, Helle Kristine
    Hovda, Tone
    Sahlberg, Kristine Kleivi
    Torland, Lilly Anne
    Lyngra, Marianne
    Hammarstrom, Clara Louise
    Honigsperger, Elma Bahonjic
    Noone, John Christopher
    Mathiassen, Silje
    Hurtado, Antoni
    Goel, Shom
    Koff, Andrew
    Tekpli, Xavier
    Kristensen, Vessela N.
    Geisler, Juergen
    [J]. FUTURE ONCOLOGY, 2024,
  • [22] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer
    Jung, Wonguen
    Kim, Kyubo
    Moon, Byung-In
    [J]. BREAST CARE, 2022, 17 (06) : 561 - 566
  • [23] CD133 Expression in ER-positive/HER2-negative Breast Cancer is Prognostic for Survival
    Huang, J.
    Oshi, M.
    Takabe, K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S57 - S57
  • [24] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Xinming Song
    Pintian Wang
    Ruiling Feng
    Mandika Chetry
    E. Li
    Xiaohua Wu
    Zewa Liu
    Shasha Liao
    Jing Lin
    [J]. Clinical and Translational Oncology, 2024, 26 : 389 - 397
  • [25] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    [J]. CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [26] Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
    Varella, Leticia
    Cristofanilli, Massimo
    [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 189 - 196
  • [27] High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
    Voutsadakis, Ioannis A.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [28] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Song, Xinming
    Wang, Pintian
    Feng, Ruiling
    Chetry, Mandika
    Li, E.
    Wu, Xiaohua
    Liu, Zewa
    Liao, Shasha
    Lin, Jing
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 389 - 397
  • [29] Effective sequence of endocrine therapy for ER-positive and HER2-negative metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Tashima, Rumiko
    Fujisue, Mamiko
    Nakano, Masahiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
    Hohmann, L.
    Sigurjonsdottir, K.
    Bosch, A.
    Nacer, D. F.
    Veerla, S.
    Hakkinen, J.
    Vallon-Christersson, J.
    Borg, A.
    Memari, Y.
    Davies, H.
    Nik-Zainal, S.
    Staaf, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S310 - S311
12345